Most cases of pulmonary embolism are treated with anticoagulant medicines, which reduce the blood's ability to form new clots and prevent the existing thrombus from growing while the body gradually breaks it down. Anticoagulant treatment generally lasts at least 3 months, but some people need to continue it for longer.
Not all pulmonary emboli require the same level of care. Some carefully selected low-risk patients can be treated outside hospital or discharged early; higher-risk cases require hospitalization and monitoring, while a pulmonary embolism with hemodynamic instability may require urgent reperfusion with thrombolysis or, in selected cases, catheter-based procedures or surgery.
Treatment does not depend solely on the visible size of the thrombus. Blood pressure, oxygenation, right ventricular function, biomarkers, bleeding risk, associated diseases and social circumstances all contribute to deciding where and how a person should be treated.
The main points to know are:
The cornerstone of treatment for pulmonary embolism in the vast majority of patients is anticoagulation. Anticoagulants do not immediately 'dissolve' the clot: they limit the formation and extension of thrombosis, reducing the risk of new emboli and allowing the body's natural systems to remodel the thrombus over time.
When pulmonary embolism is strongly suspected and investigations cannot be completed promptly, guidelines recommend starting temporary anticoagulant treatment in certain situations while awaiting diagnostic confirmation, after considering contraindications and bleeding risk.
Available medicines include direct oral anticoagulants, heparins and vitamin K antagonists. In eligible patients, current guidelines generally favor direct oral anticoagulants over vitamin K antagonists because they allow simpler regimens and do not require routine INR monitoring.
The appropriate choice is not the same for everyone. Kidney and liver function, pregnancy, antiphospholipid antibody syndrome, cancer, drug interactions, body weight, bleeding risk and other conditions may influence which medicine is most appropriate. Some anticoagulants can be started directly by mouth, whereas others require an initial course of heparin.
For confirmed pulmonary embolism, anticoagulant treatment is generally recommended for at least 3 months. This does not mean that everyone should stop taking the medicine after three months. That is the minimum duration of initial treatment, after which the balance between the risk of another thrombosis and the risk of bleeding is reassessed.
When the embolism was provoked by a major transient factor that has resolved, such as surgery, ending treatment after the planned course may be reasonable. If, on the other hand, the event has no obvious transient cause, persistent risk factors are present or repeated episodes have occurred, extended anticoagulation may be indicated.
The decision must be reassessed over time. Age, previous bleeding episodes, kidney function, other medicines, cancer and changes in health status may alter the balance between benefit and risk.
The anticoagulant must not be stopped without medical advice simply because the person feels well or shortness of breath and pain have disappeared: the effectiveness of treatment also depends on taking it consistently.
Pulmonary embolism does not automatically require a long hospital stay. Guidelines allow outpatient treatment or early discharge for selected people at low risk of complications, provided a structured assessment has been carried out and treatment, understanding of the regimen, access to care and prompt follow-up are ensured.
Tools such as PESI, sPESI and the Hestia criteria help clinicians identify potentially eligible patients, but do not replace clinical judgment. Even someone classified as low risk may need to remain in hospital if they require oxygen, have a significant bleeding risk, experience uncontrolled pain, have other acute illnesses or lack safe conditions for home management.
Hospitalization is generally necessary when higher-risk features are present: unstable blood pressure, significant hypoxemia, important comorbidities or signs of right ventricular strain. In intermediate-risk cases, echocardiography or CT may show right ventricular dysfunction and troponin may be elevated; some of these patients require monitoring because they may deteriorate rapidly.
The specialist distinction between low-risk pulmonary embolism, intermediate-risk pulmonary embolism and high-risk pulmonary embolism is specifically intended to link prognosis, monitoring intensity and treatment strategies.
Systemic thrombolysis uses fibrinolytic medicines to achieve faster reperfusion, but increases the risk of major bleeding and intracranial hemorrhage. It is therefore not the standard treatment for every pulmonary embolism. It is mainly indicated when the embolism causes hemodynamic instability, such as shock or persistent hypotension, and the immediate risk from pulmonary obstruction outweighs the bleeding risk.
Routine systemic thrombolysis is not recommended in stable intermediate-risk patients. It may become a rescue treatment if hemodynamic deterioration occurs.
When thrombolysis is contraindicated or insufficient, or when a multidisciplinary assessment identifies a specific indication, some centers may use percutaneous catheter-based treatments to fragment, aspirate or locally treat the thrombus. Surgical embolectomy is another option in selected situations, particularly severe cases in which thrombolysis cannot be used or has failed.
An inferior vena cava filter is not a usual alternative to anticoagulation. It is considered mainly when there is an absolute contraindication to anticoagulant treatment or in exceptional circumstances, because it carries risks of its own and does not treat the pulmonary embolism already present.
The principal adverse effect of anticoagulants is bleeding. Small bruises or minor bleeding may occur, but blood in the urine or stools, vomiting blood, bleeding that will not stop, a sudden severe headache after trauma or neurological symptoms require urgent assessment. A fall involving a head injury should also be reported, because internal bleeding may not be immediately apparent.
Before taking new medicines, over-the-counter products or supplements, possible interactions should be checked. Nonsteroidal anti-inflammatory drugs, antiplatelet agents and other medicines may increase bleeding risk in certain combinations.
The person should know which anticoagulant they are taking, the dosing schedule and what to do if a dose is missed, according to the specific instructions received. Doubling doses or changing treatment independently is not appropriate.
The subsequent phase includes follow-up visits, resumption of activity, assessment of recurrence risk and attention to any persistent dyspnea. These issues are addressed separately in the guide on what to do after pulmonary embolism, to avoid confusing acute treatment with follow-up.
What is the main treatment for pulmonary embolism?
For most patients it is anticoagulation. The medicine is chosen according to clinical circumstances, contraindications, interactions and individual characteristics.
How long does anticoagulant treatment last?
Generally at least 3 months. After this period, a decision is made about stopping or continuing treatment by assessing the cause of the event, recurrence risk and bleeding risk.
Does pulmonary embolism always require hospitalization?
No. Some carefully selected low-risk patients with appropriate follow-up arrangements can be treated at home or discharged early.
When is thrombolysis used?
Mainly when the embolism causes hemodynamic instability. It is not routinely used in stable intermediate-risk patients, because the benefit of reperfusion must be balanced against an increased risk of severe bleeding.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.